Immunogenicity and Safety According to Immunosuppressive Drugs and Different COVID-19 Vaccine Platforms in Immune-Mediated Disease: Data from SAFER Cohort

Background/Objectives: The effectiveness of COVID-19 vaccine in patients with immune-mediated inflammatory diseases (IMID) depends on the underlying disease, immunosuppression degree and the vaccine regimens. We evaluate the safety and immunogenicity of different COVID-19 vaccine schedules. Methods:...

Full description

Saved in:
Bibliographic Details
Main Authors: Ketty Lysie Libardi Lira Machado, Ana Paula Neves Burian, Olindo Assis Martins-Filho, José Geraldo Mill, Lunara Baptista Ferreira, Karina Rosemarie Lallemand Tapia, Anna Carolina Simões Moulin, Isac Ribeiro Moulaz, Priscila Dias Cardoso Ribeiro, Vanessa de Oliveira Magalhães, Erika Biegelmeyer, Flávia Maria Matos Melo Campos Peixoto, Sandra Lúcia Euzébio Ribeiro, Camila Maria Paiva França Telles, Juliana Bühring, Natalia Sarzi Sartorio, Vanessa Hax, Rodrigo Poubel Vieira de Rezende, Katia Lino Baptista, Ana Karla Guedes de Melo, Vitor Alves Cruz, Rejane Maria Rodrigues de Abreu Vieira, Renata Henriques de Azevedo, Valderilio Feijó Azevedo, Marcelo de Medeiros Pinheiro, Odirlei André Monticielo, Edgard Torres Dos Reis Neto, Andréa Teixeira-Carvalho, Ricardo Machado Xavier, Emilia Inoue Sato, Viviane Angelina de Souza, Gilda Aparecida Ferreira, Gecilmara Salviato Pileggi, Valeria Valim
Format: Article
Language:English
Published: MDPI AG 2024-12-01
Series:Vaccines
Subjects:
Online Access:https://www.mdpi.com/2076-393X/12/12/1367
Tags: Add Tag
No Tags, Be the first to tag this record!